Zydus Life gains over 3% on launch of bladder control drug

Incred Equities estimates Mirabegron to be a $75-80 million opportunity for Zydus Lifesciences, as the company also enjoys a 180-day exclusivity period

Related Keywords

Zydus Lifesciences ,Aurobindo Pharma ,Zydus Lifescience ,National Stock Exchange ,Drug Administration ,Zydus Life ,National Stock ,Incred Equities ,Alkem Labs ,Emerging Markets ,Uzzing Stocks ,Ydus Life Drug Launch ,Ydus Life Bladder Drug ,Drug Launch ,Ydus Life Stock Reaction ,Zydus Life Share Price , ,